Technology
Health
Biotechnology

Oragenics

$0.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (1.64%) Today
+$0.02 (3.23%) After Hours

Why Robinhood?

You can buy or sell Oragenics and other stocks, options, ETFs, and crypto commission-free!

About

Oragenics Inc., also called Oragenics, is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of lantibiotics and genetically engineered bacterial strains. Read More The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.

Employees
6
Headquarters
Tampa, Florida
Founded
1996
Market Cap
11.24M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.82M
High Today
$0.63
Low Today
$0.61
Open Price
$0.63
Volume
699.78K
52 Week High
$3.74
52 Week Low
$0.38

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America

News

Seeking AlphaMar 20

Oragenics -13.1% on proposed equity offering

Oragenics (NYSEMKT:OGEN) has slipped 13.1% after announcing a proposed equity offering. Terms weren't disclosed, but it will offer shares and warrants via H.C. Wainwright & Co. The underwriter will get a 30-day option to buy additional shares/warrants at the public offering price. Net proceeds will go to fund the AG013 research, clinical trials, preclinical development of the lantibiotics program, and general purposes....

135
Markets InsiderMar 20

Organics Announces Proposed Underwritten Public Offering

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that it has commenced a proposed underwritten public offering of common stock of the Company, together with warrants to purchase shares of common stock. In addition, the Company expects to grant the underwriter of the offering, a 30-day option to purchase additional shares of common stock and/or warrants at the public offering price, l...

5,369
Markets InsiderMar 15

Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the enrollment of the 60th patient in its Phase 2 double blind, placebo controlled clinical trial of AG013 (NCT03234465). AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis bacteria strain that contains the coding sequence for human trefoil family factor 1 (hTFF1), which is continually secreted by the bacteria. ...

5,430

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
Expected Mar 25, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.